Adare Pharma Solutions

Frontida Biopharm, Inc. is a Contract Development and Manufacturing Organization that specializes in supporting biopharmaceutical companies with the scale-up and commercial production of immediate and controlled release oral solid dose products. The company is capable of manufacturing Highly Potent Active Ingredient products and combination products, as well as those classified under DEA schedules II to V. Frontida employs a patented Duragran® granulation process, which streamlines production by eliminating traditional manufacturing steps like extrusion and compaction. This innovative approach enhances drug loading and results in more efficiently engineered controlled release products at lower production costs. Additionally, Frontida provides services such as clinical trial materials manufacturing, serialized packaging, warehousing, and stability services, making it a comprehensive partner for biopharmaceutical clients.

Orbis Biosciences, Inc. specializes in developing controlled-release delivery systems applicable across various sectors, including pharmaceuticals, consumer products, chemicals, and food and beverage industries. Established in 2007 and based in Lenexa, Kansas, the company utilizes precision particle fabrication technology to allow businesses to innovate and enhance their product offerings by controlling critical particle parameters such as size, encapsulation material, shell thickness, and porosity. This scalability enables Orbis Biosciences to provide tailored solutions for a diverse range of applications, from drug formulations to agricultural compounds and novel food processing techniques. The company's technologies focus on creating uniform microspheres and microcapsules, optimizing both oral and injectable pharmaceutical products through customized drug release and format flexibility, ultimately improving compliance for end users. As of April 30, 2020, Orbis operates as a subsidiary of Adare Pharmaceuticals, Inc.